SlideShare a Scribd company logo
1 of 55
Download to read offline
Company Presentation
July 2007
2
This presentation contains “forward-looking statements” as defined under
the federal securities laws. Actual results could vary materially. Factors
that could cause actual results to vary materially are described in our filings
with the Securities and Exchange Commission.
You should pay particular attention to the “risk factors” contained in
documents we file from time to time with the Securities and Exchange
Commission. The risks identified therein, as well as others not identified by
the Company, could cause the Company’s actual results to differ materially
from those expressed in any forward-looking statements.
Legal NoticeLegal Notice
Cautionary Statement Concerning
Forward-Looking Statements
3
Stem Cell Based TherapyStem Cell Based Therapy
Scientists worldwide believe stem cell-
based therapies have the potential to
restore healthy function of diseased
or damaged tissues
Goal is to develop therapies that work
by transplanting cells and tissues
derived from stem cells into the
body, using the body’s natural
powers of regeneration and healing
4
Company MissionCompany Mission
Translating World Class Stem Cell
Research into Proprietary Human
Therapeutic Programs
5
Recent EventsRecent Events
Driving Forward into the Clinic
Acquiring Mytogen and Myoblast Program
Phase II Clinical Trial for the Treatment of Chronic Heart Failure
Commencing GLP Studies for RPE Program
Preclinical Safety Studies for the Treatment of AMD and Retinal
Degenerative Disease
Commencing Preclinical Studies for Hemangioblast Program
Preclinical Studies for the Replacement of Red Blood Cells and
the Treatment of Eye Disease (Diabetic Retinopathy and Branch
Vein Occlusion)
6
Key Highlights of Mytogen AcquisitionKey Highlights of Mytogen Acquisition
Target Market for Myoblast Program
Chronic Heart Failure - treat scar tissue
caused by heart
attack
Clearance from FDA to Proceed with
Phase II Clinical Trials
Experienced Mytogen Development
Team – Together for over Ten Years
Strong Intellectual Property – Mytogen
Licensed from GenVec who Acquired
from Diacrin
Transaction to Close in July – ACT
Acquiring Mytogen for Common Stock
Charlestown, MA GMP Facility
7
Key Highlights of Mytogen AcquisitionKey Highlights of Mytogen Acquisition
Gained Clearance from FDA to Proceed
with Phase II Multi-Center Clinical Trial
3 Phase I Clinical Studies Completed
Dosed in 42 patients
No safety concerns
Strong indications of efficacy
Phase lb Catheter Trial Nearly Complete
No adverse effects associated with cells,
no arrhythmia concerns
Highly significant improvement in NYHA
classification
Improvement in ventricular volumes
2.8
2.4
1.9
2.4
1.4
2.6
1
1.5
2
2.5
3
Myoblast Control
AverageNYHAClass
3 mos: p = 0.0009, n = 23
6 mos: p < 0.0001, n = 23
A decrease in NYHA score represents an
improvement in symptoms and an increase
represents a worsening.
Phase Ib Clinical Trial Results – NYHA Classification
8
Key Investment HighlightsKey Investment Highlights
ACT Proprietary Human Therapeutic Programs
Myoblast Program Treatment of Heart Attack Phase II
and Heart Failure
RPE Program Treatment of AMD and Retinal Preclinical
Degenerative Diseases
Hemangioblast Treatment of Disease and Disorders Preclinical
Program of the Blood and Vascular System
Dermal Program Treatment of Wounds, Burns Preclinical
and Scars
9
Key Investment HighlightsKey Investment Highlights
ACT Proprietary Enabling Technology Platforms
Blastomere Program First Proven Alternative Method for hESC Derivation
ACTCellerate High Throughput Derivation and Differentiation of
Program Therapeutic Cell Types
GMP Manufacturing Producing GMP-Compliant, Pathogen-Free Banks
Program of hESCs and Therapeutic Cell Types
10
World Class Scientific Team Lead By:
Dr. Michael West President and Chief Scientific Officer
Dr. Robert Lanza VP of Research & Scientific Development
Dr. Pedro Huertas Chief Development Officer
Industry-Leading Intellectual Property Portfolio
More than 300 patents and patent applications related to
stem cell therapy and regenerative medicine
Key Investment HighlightsKey Investment Highlights
ACT Therapeutics:
Myoblast Program
12
Myoblast Stem Cell TherapyMyoblast Stem Cell Therapy
Outpatient therapy to improve
cardiac function in heart failure
patients
Harvest muscle stem cells
(Myoblasts) from patient’s thigh
Expand cells using proprietary
culturing process
Identify and map scarred regions
of the heart with 3-D imaging
technique
Inject cells with minimally-invasive
cardiac catheter: no general
anesthesia
13
Myoblast Clinical Trial SummaryMyoblast Clinical Trial Summary
Escalating -
30, 100, 300 and
600 MM Cells
Single Dose -
300 MM Cells
Escalating –
10, 30, 100 and
300 MM Cells
Single Dose -
300 MM Cells
Dose
Safe at all doses,
improved
symptoms and
function
Safety
Catheter Injection
23 Patients
(12 treated,
11 control)
Phase 1b
Catheter
Result
Primary
Endpoint
Indication
Patients
Phase 1b
CABG
Phase 1
CABG
Phase 1
LVAD
Survival of cells
(cardiac imaging),
improved
symptoms and
function
Dose escalation,
Safe at all doses
Demonstrated
cell survival in
humans
SafetySafetySafety
+CABG+CABG
LVAD Bridge to
Transplant
12 patients12 patients6 patients
14
Phase Ib Catheter Trial SummaryPhase Ib Catheter Trial Summary
First U.S. randomized trial of catheter-delivered muscle cells
Core laboratory analysis of objective endpoints
Only trial with direct injection into scar (other stem cells must
be delivered to viable tissue for benefit)
Catheter delivery process without any complications
No deaths, no loss to follow-up
Ongoing follow-up data
15
3-D NOGA Mapping of Myoblast Injections3-D NOGA Mapping of Myoblast Injections
5.7 mV 8.6 mV
Injections of 600 million cells into
infarct region shown in red
3 months post reveals significant
improvement in viability of the heart
16
Phase Ib Clinical Trial ResultsPhase Ib Clinical Trial Results
2.8
2.4
1.9
2.4
1.4
2.6
1
1.5
2
2.5
3
Myoblast Control
AverageNYHAClass
3 mos: p = 0.0009, n = 23
6 mos: p < 0.0001, n = 23
A decrease in NYHA score represents an improvement in
symptoms and an increase represents a worsening
NYHA Classification of Heart Failure Symptoms
Baseline 3mos 6mos Baseline 3mos 6mos
17
Phase Ib Clinical Trial ResultsPhase Ib Clinical Trial Results
-0.6
-0.4
-1
-1.4
0.2
-1.6
-1.4
-1.2
-1
-0.8
-0.6
-0.4
-0.2
0
0.2
0.4
Ave.ChangeinNYHA
Control
ß-blockers
ACE Inhibitors
CRT
Myoblasts
Control ß-blockers* ACE Inhibitors#
CRT†
Myoblasts
* Lombardo et al., 2006 Am J Cardiovasc Drugs 6:259-63
†
McAllister et al., 2004 Ann Intern Med 141:381-90
# Sliwa et al., 2004 JACC 44:1825-30
Change in NYHA at 6mos post treatment
Comparative Effects of Heart Failure Treatments on NYHA
18
Phase Ib Clinical Trial ResultsPhase Ib Clinical Trial Results
Minnesota Living with Heart Failure Questionnaire (MLHFQ)
47 47
28
46
0
10
20
30
40
50
Myoblast Control
p = 0.017, n = 23
Baseline 6mos Baseline 6mos
* Improvement in patient quality of life (QOL) scores for all patients
19
Phase Ib Clinical Trial ResultsPhase Ib Clinical Trial Results
Average change in distance walked in 6 minutes from 3 months to 6 months
for all patients
81
-9
-50
0
50
100
Feet
Myoblast Control
6 Minute Walk Test
20
Phase Ib Clinical Trial ResultsPhase Ib Clinical Trial Results
Ventrical Volumes: End Systolic and End Diastolic Diameters
End Systolic Diameter at 3 and 6 mos as measured by
independent echocardiography core lab for all patients
5.52
4.89
5.4
4.99
5.41
5.08
4.8
4.9
5
5.1
5.2
5.3
5.4
5.5
5.6
Myoblast Control
cm
p = 0.06, n = 23
Baseline 3mos 6mos Baseline 3mos 6mos
End Diastolic Diameter at 3 and 6 mos as measured by
independent echocardiography core lab for all patients
6.41
6.2
6.38
6.27
6.39
6.37
6
6.1
6.2
6.3
6.4
6.5
Myoblast Control
cm
p = 0.07, n = 23
Baseline 3mos 6mos Baseline 3mos 6mos
21
Phase Ib Clinical Trial ResultsPhase Ib Clinical Trial Results
NYHA Classification at 6 month vs Baseline for all Patients
36%64%0%Control
0%17%83%Myoblast
WorsenedNo ChangeImproved
22
Plan for Phase II Clinical TrialPlan for Phase II Clinical Trial
160 total patients (2:1 treatment vs control)
Double-blind, placebo (sham procedure) controlled
Catheter delivery of cells: percutaneous
Three month, six month, and 12 month follow-up
Endpoints: Improvement in HF symptoms and Ventricular Volumes
Primary endpoint: Improvement in quality of life measure “Kansas City
Cardiomypathy Questionaire”
Secondary endpoints: Ventricular volumes, Six minute walk test
Interim data analysis at six months by Independent Review Board
ACT Therapeutics:
RPE Program
24
RPE Anatomy and FunctionRPE Anatomy and Function
RPE
Layer
Deteriorates
in Patients
with AMD
and other
Retinal
Degenerative
Diseases
absorption of stray light
barrier
vitamin A metabolism and
transport
phagocytosis of shed
photoreceptor segments
some functions of RPE
25
RPE ProgramRPE Program
2006 Milestone
Achieved:
Published Data
Showing hESC-
derived RPE
Cells Rescue
Visual Function
in
RCS Rats
26
RPE Rescue in the RCS RatRPE Rescue in the RCS Rat
RPE: essential for the survival of photoreceptors in the retina;
believed to play a critical role in healthy vision
RCS retina at P100 with
RPE-9 injection:
A: low power view of retina
showing extensive rescue;
B: high power of outline b
showing rescued
photoreceptors;
C: high power of outline c
showing non-rescue area.
Photoreceptor
Rescue in RCS Rat
by transplanted
H9-RPE cells
27
RPE Program CollaborationRPE Program Collaboration
2007 Milestone Achieved - Preclinical Development Collaboration
with Casey Eye Institute at Oregon Health & Science University
Dr. Raymond Lund Leading Researcher in Retinal
Degenerative Disease
Dr. Peter Francis Senior Researcher and Clinician
Dr. Richard Weleber Senior Clinician
OHSU Team is Conducting Dosage Studies in the RCS Rat
OHSU Team is Advising on RPE Program Safety Studies
Additionally, OHSU Team is Advising on Plans for IND and
Phase I Human Clinical Trials
28
RPE Program - GLP Safety StudiesRPE Program - GLP Safety Studies
2007 Milestone Achieved – Hired MPI Research to conduct our GLP
Safety Studies for the RPE Program
Initial Pilot Studies Commenced initial studies to
demonstrate cell survival and validation
of controls
Pivotal Studies Full safety and tumorigenicity studies to
demonstrate safety of cells in animal
models
FDA Dialogue Company has initiated discussions with
FDA and is planning for further
discussions in 2007 in regard to IND
submission
ACT Therapeutics:
Hemangioblast Program
30
The Hemangioblast CellThe Hemangioblast Cell
Pre-cursor to all cell types of the blood and the
vascular system
31
Hemangioblast ProgramHemangioblast Program
2006 Milestone Achieved: Hemangioblast Cells
Generated from Blastomere Derived hESC Lines
40X 10X
32
Hemangioblast ProgramHemangioblast Program
2007 Milestone
Achieved:
Published Data
Showing
Hemangioblast
Function In Vivo in
Nature Methods
33
Hemangioblast ProgramHemangioblast Program
Repair of Ischemic Retinal Vasculatures
Mouse Rat
34
Hemangioblast ProgramHemangioblast Program
Restoration of Blood Flow in Ischemic Limbs (Rat)
35
Hemangioblast ProgramHemangioblast Program
Increase in Survival Rate in Infacted Heart (Mouse)
36
Hemangioblast ProgramHemangioblast Program
Significant Breakthrough in Scaled
Manufacture of Hemangioblasts Cells
Well characterized - make all cells
of the blood and vascular tissues
Significant Collaborations underway
to generate proof of concept data in a
wide range of indications
Plan to generate Hemangioblasts under
GMP in 2007 and commence additional
preclinical studies for target indications
ACT Therapeutics:
Dermal Program
38
Skin: Dermal Cells for Wound and Burn RepairSkin: Dermal Cells for Wound and Burn Repair
ES dermal cells possess unique
healing capacities of early skin cells
to heal wounds without scarring.
ACTC is researching ES dermal cell
technology that may someday repair
skin.
Large application for therapies to repair
damage from burns, wounds and surgical
procedures, quickly and without scarring
Cells successfully isolated in our California labs
ACT Technology:
Blastomere Program
40
Blastomere Program–Most RecognizedBlastomere Program–Most Recognized
41
Success in HumanSuccess in Human
2006 Milestone
Achieved:
Derivation of
Human hESC
Lines Published
in Nature
42
First Proven Alternative MethodFirst Proven Alternative Method
Enables Derivation of New hESC Lines via
Preimplantation Genetic Diagnosis (PGD)
Method, Preserving Development Potential of
the Embryo
First Proven Alternative; Presents Solution to
hESC Controversy
Blastomere hESC Lines May Be Eligible for
Federal Funding; Company Seeking RulingHemangioblastsHemangioblasts
Differentiated fromDifferentiated from
BlastomereBlastomere hESChESC LinesLines
ACT Technology:
ACTCellerate Program
44
ACTCellerate – A Sleeping BeautyACTCellerate – A Sleeping Beauty
2006 Milestone Achieved:
Announced proprietary high throughput
technology platform for discovering large
number of therapeutically useful, hESC-derived
cell types
45
ACTCellerate ProgramACTCellerate Program
Cell
Sorting
Cell
Sorting
Gene Expression
Profile
Scaling in Rollers
hES Cell Line
ACTCellerate Cell Lines
LinesHuman Embryo-
Derived Cells
46
ACTCellerate ProgramACTCellerate Program
ACT162
Cardiac Progenitor
Cardiac
Muscle
ACTC
MYH7
MYL4
MYH3
TNNT2
Neuronal
NEF3
NEFL
MEIS1
CDH2
SILV
ACTCellerate Cell Lines
Lines
ACT Technology:
GMP Manufacturing Program
48
CENTRIF
CT03002
Microscope
BSC
SH-
01002
BSC
SH-
01001
Viewing Window
Sterilizer
OV-05001
CENTRIF
CT-03001
Unclassified
Pass
Thru
Warming
Oven
IN-02001
-80
Freezer
CS-04002
2-8˚C
Refrigerator
CS-01001
Tri-Gas
Incubator
IN-03001
CO2
INCUBATOR
IN-01004 (top)
IN-01003
(bottom)
CO2
INCUBATOR
IN-01001 (top)
IN-01002 (bottom)
Microscope
with
Computer
Work
Station
SH-
03001
BSC
SH-01003
FPRM198Revision5
13June06
Class 10.000
Room 198
Class 100.000
Room 199
GMP Manufacturing ProgramGMP Manufacturing Program
2006 Milestone Achieved - Company Opens GMP
Facilities in Massachusetts and California
ADVANCED CELL TECHNOLOGY
GMP MANUFACTURING
LABORATORY Rms 198/199
49
GMP Manufacturing ProgramGMP Manufacturing Program
2007 Milestone Achieved – Company Hires Dr. Pedro
Huertas as Chief Development Officer
Noted Biotech Industry Executive – Experience at
Genzyme, StemCells Inc., Novazyme, Amicus
Therapeutics
Harvard – MIT Trained Physician
M.D. from Harvard and MIT
Ph.D. from Harvard University in Cell and
Developmental Biology
M.B.A. from MIT’s Sloan School of Mgmt
Tasked with leading company’s push to the clinic
50
GMP Manufacturing ProgramGMP Manufacturing Program
Design of Master and Working hESC Banks
Unlimited Expansion of
Stem Cell Line
Master
Cell Bank
Working
Cell Bank
Bank of Differentiated Cells
Bank of
Differentiated Cells
Bank of Differentiated Cells
Single Blastomere
51
GMP Manufacturing ProgramGMP Manufacturing Program
2007 Milestone Achieved – Company Manufacturing RPE
Cells under GMP Compliant Conditions
Working Stem Cell Bank Cryopreserved RPE Cell Bank
Retinal
Pigmented
Epithelium
ACT :
Corporate Milestones
53
2007 – 2008 Corporate Milestones2007 – 2008 Corporate Milestones
Raise Additional Capital
Achieve Listing on National Exchange
Commence Phase II Clinical Trial for Myoblast Program
File INDs for RPE and Hemangioblast Programs
Announce Significant Corporate Partnership
Announce Scientific Breakthrough on Solving
Histocompatibility
54
ACTC Value PropositionACTC Value Proposition
Selected Comparable Companies (S mio., except per share data)
Osiris OSIR / $14.04 27.4 $384.7 172,590
Phase II/III Stem Cell Therapy NASDAQ
Geron Corporation GERN / $7.14 72.9 $520.5 1,660,000
Phase II Cancer / Preclinical hESCs NASDAQ
Stem Cells, Inc. STEM / $2.30 80.4 $184.9 1,215,743
Phase I Stem Cell Therapy NASDAQ
Aastrom Biosciences, Inc. ASTM / $1.35 120.0 $162.0 1,100,000
Phase II/III Stem Cell Therapy NASDAQ
ViaCell, Inc. VIAC / $5.40 38.8 $209.5 151,298
Cord Blood Storage / Preclinical NASDAQ
Advanced Cell Technology ACTC / $0.47 49.5 $23.3 1,006,000
Phase II Stem Cell Therapy / Preclinical hESCs OTCBB
* Does not include outstanding options, warrants and other common stock equivalents.
Volume
Average
DailyMarket
Capitalization
Primary
Shares
Outstanding*Name / Description / Phase Tkr / Exch
Current
Stock Price
(Jun 28th)
Thank you for your time
For more information, visit www.advancedcell.com
Advanced Cell Technology is traded on the OTC BB, symbol: ACTC

More Related Content

What's hot

Ym bio sciences corppres ash2012 dec 10 12
Ym bio sciences corppres ash2012 dec 10 12Ym bio sciences corppres ash2012 dec 10 12
Ym bio sciences corppres ash2012 dec 10 12YMBioSciences
 
New and emerging therapies for retinal diseases
New and emerging therapies for retinal diseasesNew and emerging therapies for retinal diseases
New and emerging therapies for retinal diseasesVisionary Ophthamology
 
Robert Califf slides, IOM workshop on Sharing Clinical Research Data, October...
Robert Califf slides, IOM workshop on Sharing Clinical Research Data, October...Robert Califf slides, IOM workshop on Sharing Clinical Research Data, October...
Robert Califf slides, IOM workshop on Sharing Clinical Research Data, October...Marilyn Mann
 
Nw2014 Diabetic Macular Edema Treatment Options
Nw2014 Diabetic Macular Edema Treatment OptionsNw2014 Diabetic Macular Edema Treatment Options
Nw2014 Diabetic Macular Edema Treatment OptionsNawat Watanachai
 
Mu anti cancer therapeutics - novel targets in the cholesterol biosynthetic p...
Mu anti cancer therapeutics - novel targets in the cholesterol biosynthetic p...Mu anti cancer therapeutics - novel targets in the cholesterol biosynthetic p...
Mu anti cancer therapeutics - novel targets in the cholesterol biosynthetic p...kphodel
 
Mmc1 2 The Lancet - Supplementary appendix 10/15/2014
Mmc1 2 The Lancet - Supplementary appendix 10/15/2014Mmc1 2 The Lancet - Supplementary appendix 10/15/2014
Mmc1 2 The Lancet - Supplementary appendix 10/15/2014John Redaelli
 
Acs0807 Acute Renal Failure
Acs0807 Acute Renal FailureAcs0807 Acute Renal Failure
Acs0807 Acute Renal Failuremedbookonline
 
Updates from AMD clinical trials
Updates from AMD clinical trialsUpdates from AMD clinical trials
Updates from AMD clinical trialsYasuo Yanagi
 
Peds simualtion san antonio2
Peds simualtion san antonio2Peds simualtion san antonio2
Peds simualtion san antonio2boyd888
 

What's hot (13)

Maureen Maguire April 1 2009
Maureen Maguire April 1 2009Maureen Maguire April 1 2009
Maureen Maguire April 1 2009
 
Ym bio sciences corppres ash2012 dec 10 12
Ym bio sciences corppres ash2012 dec 10 12Ym bio sciences corppres ash2012 dec 10 12
Ym bio sciences corppres ash2012 dec 10 12
 
New and emerging therapies for retinal diseases
New and emerging therapies for retinal diseasesNew and emerging therapies for retinal diseases
New and emerging therapies for retinal diseases
 
Robert Califf slides, IOM workshop on Sharing Clinical Research Data, October...
Robert Califf slides, IOM workshop on Sharing Clinical Research Data, October...Robert Califf slides, IOM workshop on Sharing Clinical Research Data, October...
Robert Califf slides, IOM workshop on Sharing Clinical Research Data, October...
 
LA SOMAZINA Y SUS USOS...
LA SOMAZINA Y SUS USOS...LA SOMAZINA Y SUS USOS...
LA SOMAZINA Y SUS USOS...
 
Stem Cell Meeting on the Mesa, Oct. 29, 2012
Stem Cell Meeting on the Mesa, Oct. 29, 2012Stem Cell Meeting on the Mesa, Oct. 29, 2012
Stem Cell Meeting on the Mesa, Oct. 29, 2012
 
Nw2014 Diabetic Macular Edema Treatment Options
Nw2014 Diabetic Macular Edema Treatment OptionsNw2014 Diabetic Macular Edema Treatment Options
Nw2014 Diabetic Macular Edema Treatment Options
 
Mu anti cancer therapeutics - novel targets in the cholesterol biosynthetic p...
Mu anti cancer therapeutics - novel targets in the cholesterol biosynthetic p...Mu anti cancer therapeutics - novel targets in the cholesterol biosynthetic p...
Mu anti cancer therapeutics - novel targets in the cholesterol biosynthetic p...
 
Mmc1 2 The Lancet - Supplementary appendix 10/15/2014
Mmc1 2 The Lancet - Supplementary appendix 10/15/2014Mmc1 2 The Lancet - Supplementary appendix 10/15/2014
Mmc1 2 The Lancet - Supplementary appendix 10/15/2014
 
Acs0807 Acute Renal Failure
Acs0807 Acute Renal FailureAcs0807 Acute Renal Failure
Acs0807 Acute Renal Failure
 
Updates from AMD clinical trials
Updates from AMD clinical trialsUpdates from AMD clinical trials
Updates from AMD clinical trials
 
Peds simualtion san antonio2
Peds simualtion san antonio2Peds simualtion san antonio2
Peds simualtion san antonio2
 
Neurotech
NeurotechNeurotech
Neurotech
 

Similar to ACTC Company Presentation, July 2007

World stem cells & regenerative medicine congress, london, may 22, 2013
World stem cells & regenerative medicine congress, london, may 22, 2013World stem cells & regenerative medicine congress, london, may 22, 2013
World stem cells & regenerative medicine congress, london, may 22, 2013Advanced Cell Technology, Inc.
 
Economic And Humanistic Outcomes Of Post Acs In Cardiac Rehabilitation Progra...
Economic And Humanistic Outcomes Of Post Acs In Cardiac Rehabilitation Progra...Economic And Humanistic Outcomes Of Post Acs In Cardiac Rehabilitation Progra...
Economic And Humanistic Outcomes Of Post Acs In Cardiac Rehabilitation Progra...guestaf1e4
 
May 2016 Corporate Presentation
May 2016 Corporate PresentationMay 2016 Corporate Presentation
May 2016 Corporate Presentationoncolyticsinc
 
YM BioSciences CorpPres ASH2012 Dec 10 12
YM BioSciences CorpPres ASH2012 Dec 10 12YM BioSciences CorpPres ASH2012 Dec 10 12
YM BioSciences CorpPres ASH2012 Dec 10 12YMBioSciences
 
CLBS Corporate Slide Presentation March 2018
CLBS Corporate Slide Presentation March 2018CLBS Corporate Slide Presentation March 2018
CLBS Corporate Slide Presentation March 2018Steve Sizer
 
Steroid Withdrawal after kidney transplantation
Steroid Withdrawal after kidney transplantationSteroid Withdrawal after kidney transplantation
Steroid Withdrawal after kidney transplantationChristos Argyropoulos
 
2010.05.20 clinicians view on regeneration
2010.05.20 clinicians view on regeneration2010.05.20 clinicians view on regeneration
2010.05.20 clinicians view on regenerationneithan
 
ACT Presentation at Rodman & Renshaw Annual Global Investment Conference, Lon...
ACT Presentation at Rodman & Renshaw Annual Global Investment Conference, Lon...ACT Presentation at Rodman & Renshaw Annual Global Investment Conference, Lon...
ACT Presentation at Rodman & Renshaw Annual Global Investment Conference, Lon...Advanced Cell Technology, Inc.
 
ACT Presentation at the 11th Annual B. Riley Investor Conference in Santa Mon...
ACT Presentation at the 11th Annual B. Riley Investor Conference in Santa Mon...ACT Presentation at the 11th Annual B. Riley Investor Conference in Santa Mon...
ACT Presentation at the 11th Annual B. Riley Investor Conference in Santa Mon...Advanced Cell Technology, Inc.
 
Galena presentation 13 sept 16
Galena presentation   13 sept 16Galena presentation   13 sept 16
Galena presentation 13 sept 16Galenabio
 
CARDIAC REHABILITATION IN SARAWAK GENERAL HOSPITAL IN MALAYSIA Research Area:...
CARDIAC REHABILITATION IN SARAWAK GENERAL HOSPITAL IN MALAYSIA Research Area:...CARDIAC REHABILITATION IN SARAWAK GENERAL HOSPITAL IN MALAYSIA Research Area:...
CARDIAC REHABILITATION IN SARAWAK GENERAL HOSPITAL IN MALAYSIA Research Area:...lawrenceanchah
 
IGX Investor Presentation
IGX Investor PresentationIGX Investor Presentation
IGX Investor PresentationItelGenx
 
Act corporate-presentation jan13
Act corporate-presentation jan13Act corporate-presentation jan13
Act corporate-presentation jan13Company Spotlight
 
5943408.ppt
5943408.ppt5943408.ppt
5943408.ppttttran
 

Similar to ACTC Company Presentation, July 2007 (20)

Act corp-pres-may13
Act corp-pres-may13Act corp-pres-may13
Act corp-pres-may13
 
World stem cells & regenerative medicine congress, london, may 22, 2013
World stem cells & regenerative medicine congress, london, may 22, 2013World stem cells & regenerative medicine congress, london, may 22, 2013
World stem cells & regenerative medicine congress, london, may 22, 2013
 
Economic And Humanistic Outcomes Of Post Acs In Cardiac Rehabilitation Progra...
Economic And Humanistic Outcomes Of Post Acs In Cardiac Rehabilitation Progra...Economic And Humanistic Outcomes Of Post Acs In Cardiac Rehabilitation Progra...
Economic And Humanistic Outcomes Of Post Acs In Cardiac Rehabilitation Progra...
 
May 2016 Corporate Presentation
May 2016 Corporate PresentationMay 2016 Corporate Presentation
May 2016 Corporate Presentation
 
YM BioSciences CorpPres ASH2012 Dec 10 12
YM BioSciences CorpPres ASH2012 Dec 10 12YM BioSciences CorpPres ASH2012 Dec 10 12
YM BioSciences CorpPres ASH2012 Dec 10 12
 
CLBS Corporate Slide Presentation March 2018
CLBS Corporate Slide Presentation March 2018CLBS Corporate Slide Presentation March 2018
CLBS Corporate Slide Presentation March 2018
 
Steroid Withdrawal after kidney transplantation
Steroid Withdrawal after kidney transplantationSteroid Withdrawal after kidney transplantation
Steroid Withdrawal after kidney transplantation
 
2010.05.20 clinicians view on regeneration
2010.05.20 clinicians view on regeneration2010.05.20 clinicians view on regeneration
2010.05.20 clinicians view on regeneration
 
Presentation from Dr. Alan Lewis
Presentation from Dr. Alan LewisPresentation from Dr. Alan Lewis
Presentation from Dr. Alan Lewis
 
ACT Presentation at Rodman & Renshaw Annual Global Investment Conference, Lon...
ACT Presentation at Rodman & Renshaw Annual Global Investment Conference, Lon...ACT Presentation at Rodman & Renshaw Annual Global Investment Conference, Lon...
ACT Presentation at Rodman & Renshaw Annual Global Investment Conference, Lon...
 
ACT Presentation at the 11th Annual B. Riley Investor Conference in Santa Mon...
ACT Presentation at the 11th Annual B. Riley Investor Conference in Santa Mon...ACT Presentation at the 11th Annual B. Riley Investor Conference in Santa Mon...
ACT Presentation at the 11th Annual B. Riley Investor Conference in Santa Mon...
 
BioEurope Presentation, March 2010
BioEurope Presentation, March 2010BioEurope Presentation, March 2010
BioEurope Presentation, March 2010
 
Galena presentation 13 sept 16
Galena presentation   13 sept 16Galena presentation   13 sept 16
Galena presentation 13 sept 16
 
CARDIAC REHABILITATION IN SARAWAK GENERAL HOSPITAL IN MALAYSIA Research Area:...
CARDIAC REHABILITATION IN SARAWAK GENERAL HOSPITAL IN MALAYSIA Research Area:...CARDIAC REHABILITATION IN SARAWAK GENERAL HOSPITAL IN MALAYSIA Research Area:...
CARDIAC REHABILITATION IN SARAWAK GENERAL HOSPITAL IN MALAYSIA Research Area:...
 
IGX Investor Presentation
IGX Investor PresentationIGX Investor Presentation
IGX Investor Presentation
 
Lo mejor en insuficiencia cardiaca
Lo mejor en insuficiencia cardiacaLo mejor en insuficiencia cardiaca
Lo mejor en insuficiencia cardiaca
 
Biotech Showcase, San Francisco, Calif., Jan. 8, 2013
Biotech Showcase, San Francisco, Calif., Jan. 8, 2013Biotech Showcase, San Francisco, Calif., Jan. 8, 2013
Biotech Showcase, San Francisco, Calif., Jan. 8, 2013
 
Act corporate-presentation jan13
Act corporate-presentation jan13Act corporate-presentation jan13
Act corporate-presentation jan13
 
Snti 102013
Snti 102013Snti 102013
Snti 102013
 
5943408.ppt
5943408.ppt5943408.ppt
5943408.ppt
 

More from Advanced Cell Technology, Inc.

2014 BIO CEO Corporate Presentation, NY, NY Feb 11, 2014
2014 BIO CEO Corporate Presentation, NY, NY Feb 11, 20142014 BIO CEO Corporate Presentation, NY, NY Feb 11, 2014
2014 BIO CEO Corporate Presentation, NY, NY Feb 11, 2014Advanced Cell Technology, Inc.
 
2013 Aegis Capital Healthcare Conference, Sept 26th 2013
2013 Aegis Capital Healthcare Conference, Sept 26th 20132013 Aegis Capital Healthcare Conference, Sept 26th 2013
2013 Aegis Capital Healthcare Conference, Sept 26th 2013Advanced Cell Technology, Inc.
 
Rodman and Rendshaw 2013 Annual Global Investment Conference, NYC, Sept 2013
Rodman and Rendshaw 2013 Annual Global Investment Conference, NYC, Sept 2013Rodman and Rendshaw 2013 Annual Global Investment Conference, NYC, Sept 2013
Rodman and Rendshaw 2013 Annual Global Investment Conference, NYC, Sept 2013Advanced Cell Technology, Inc.
 
ARM's Regen Med Investor Day, New York City, April 17, 2013
ARM's Regen Med Investor Day, New York City, April 17, 2013ARM's Regen Med Investor Day, New York City, April 17, 2013
ARM's Regen Med Investor Day, New York City, April 17, 2013Advanced Cell Technology, Inc.
 
BIO CEO & Investor Conference, New York City, February 11, 2013
BIO CEO & Investor Conference, New York City, February 11, 2013BIO CEO & Investor Conference, New York City, February 11, 2013
BIO CEO & Investor Conference, New York City, February 11, 2013Advanced Cell Technology, Inc.
 
Terrapinn's Stem Cells USA & Regenerative Medicine Congress, Boston, Mass., S...
Terrapinn's Stem Cells USA & Regenerative Medicine Congress, Boston, Mass., S...Terrapinn's Stem Cells USA & Regenerative Medicine Congress, Boston, Mass., S...
Terrapinn's Stem Cells USA & Regenerative Medicine Congress, Boston, Mass., S...Advanced Cell Technology, Inc.
 
Clinical Outlooks for Regenerative Medicine, Boston. June 2012
Clinical Outlooks for Regenerative Medicine, Boston. June 2012Clinical Outlooks for Regenerative Medicine, Boston. June 2012
Clinical Outlooks for Regenerative Medicine, Boston. June 2012Advanced Cell Technology, Inc.
 
2012 World Stem Cell & Regenerative Medicine Congress, London
2012 World Stem Cell & Regenerative Medicine Congress, London2012 World Stem Cell & Regenerative Medicine Congress, London
2012 World Stem Cell & Regenerative Medicine Congress, LondonAdvanced Cell Technology, Inc.
 
Roth Capital 24th Annual Growth Stock Conference, Los Angeles
Roth Capital 24th Annual Growth Stock Conference, Los AngelesRoth Capital 24th Annual Growth Stock Conference, Los Angeles
Roth Capital 24th Annual Growth Stock Conference, Los AngelesAdvanced Cell Technology, Inc.
 
Regenerative Medicine Track at Biotech Showcase 2012, San Francisco
Regenerative Medicine Track at Biotech Showcase 2012, San FranciscoRegenerative Medicine Track at Biotech Showcase 2012, San Francisco
Regenerative Medicine Track at Biotech Showcase 2012, San FranciscoAdvanced Cell Technology, Inc.
 
Presentation at Stem Cell Meeting on the Mesa, La Jolla, Calif., November 30,...
Presentation at Stem Cell Meeting on the Mesa, La Jolla, Calif., November 30,...Presentation at Stem Cell Meeting on the Mesa, La Jolla, Calif., November 30,...
Presentation at Stem Cell Meeting on the Mesa, La Jolla, Calif., November 30,...Advanced Cell Technology, Inc.
 
Presentation at Stem Cells USA & Regenerative medicine Congress 2011 in Bosto...
Presentation at Stem Cells USA & Regenerative medicine Congress 2011 in Bosto...Presentation at Stem Cells USA & Regenerative medicine Congress 2011 in Bosto...
Presentation at Stem Cells USA & Regenerative medicine Congress 2011 in Bosto...Advanced Cell Technology, Inc.
 
Presentation at the Rodman & Renshaw Global Investment Conference, NYC, Sept....
Presentation at the Rodman & Renshaw Global Investment Conference, NYC, Sept....Presentation at the Rodman & Renshaw Global Investment Conference, NYC, Sept....
Presentation at the Rodman & Renshaw Global Investment Conference, NYC, Sept....Advanced Cell Technology, Inc.
 
Presentation at World Stem Cell & Regenerative Medicine Congress, London. May...
Presentation at World Stem Cell & Regenerative Medicine Congress, London. May...Presentation at World Stem Cell & Regenerative Medicine Congress, London. May...
Presentation at World Stem Cell & Regenerative Medicine Congress, London. May...Advanced Cell Technology, Inc.
 
Presentation at Bio-Europe Spring 2011 Conference, Milan, Italy. March 2011
Presentation at Bio-Europe Spring 2011 Conference, Milan, Italy. March 2011Presentation at Bio-Europe Spring 2011 Conference, Milan, Italy. March 2011
Presentation at Bio-Europe Spring 2011 Conference, Milan, Italy. March 2011Advanced Cell Technology, Inc.
 
Presentation at BIO CEO & Investor Conference, New York City. February 2011
Presentation at BIO CEO & Investor Conference, New York City. February 2011Presentation at BIO CEO & Investor Conference, New York City. February 2011
Presentation at BIO CEO & Investor Conference, New York City. February 2011Advanced Cell Technology, Inc.
 

More from Advanced Cell Technology, Inc. (20)

2014 BIO CEO Corporate Presentation, NY, NY Feb 11, 2014
2014 BIO CEO Corporate Presentation, NY, NY Feb 11, 20142014 BIO CEO Corporate Presentation, NY, NY Feb 11, 2014
2014 BIO CEO Corporate Presentation, NY, NY Feb 11, 2014
 
2014 Biotech Showcase Presentation, January 13, 2014
2014 Biotech Showcase Presentation, January 13, 20142014 Biotech Showcase Presentation, January 13, 2014
2014 Biotech Showcase Presentation, January 13, 2014
 
ACT Annual Shareholders' Meeting, October 22, 2013
ACT Annual Shareholders' Meeting, October 22, 2013ACT Annual Shareholders' Meeting, October 22, 2013
ACT Annual Shareholders' Meeting, October 22, 2013
 
2013 Aegis Capital Healthcare Conference, Sept 26th 2013
2013 Aegis Capital Healthcare Conference, Sept 26th 20132013 Aegis Capital Healthcare Conference, Sept 26th 2013
2013 Aegis Capital Healthcare Conference, Sept 26th 2013
 
Rodman and Rendshaw 2013 Annual Global Investment Conference, NYC, Sept 2013
Rodman and Rendshaw 2013 Annual Global Investment Conference, NYC, Sept 2013Rodman and Rendshaw 2013 Annual Global Investment Conference, NYC, Sept 2013
Rodman and Rendshaw 2013 Annual Global Investment Conference, NYC, Sept 2013
 
ARM's Regen Med Investor Day, New York City, April 17, 2013
ARM's Regen Med Investor Day, New York City, April 17, 2013ARM's Regen Med Investor Day, New York City, April 17, 2013
ARM's Regen Med Investor Day, New York City, April 17, 2013
 
BIO CEO & Investor Conference, New York City, February 11, 2013
BIO CEO & Investor Conference, New York City, February 11, 2013BIO CEO & Investor Conference, New York City, February 11, 2013
BIO CEO & Investor Conference, New York City, February 11, 2013
 
Terrapinn's Stem Cells USA & Regenerative Medicine Congress, Boston, Mass., S...
Terrapinn's Stem Cells USA & Regenerative Medicine Congress, Boston, Mass., S...Terrapinn's Stem Cells USA & Regenerative Medicine Congress, Boston, Mass., S...
Terrapinn's Stem Cells USA & Regenerative Medicine Congress, Boston, Mass., S...
 
Rodman Conference, September 2012
Rodman Conference, September 2012Rodman Conference, September 2012
Rodman Conference, September 2012
 
2012 BIO International Convention, Boston
2012 BIO International Convention, Boston2012 BIO International Convention, Boston
2012 BIO International Convention, Boston
 
Clinical Outlooks for Regenerative Medicine, Boston. June 2012
Clinical Outlooks for Regenerative Medicine, Boston. June 2012Clinical Outlooks for Regenerative Medicine, Boston. June 2012
Clinical Outlooks for Regenerative Medicine, Boston. June 2012
 
2012 World Stem Cell & Regenerative Medicine Congress, London
2012 World Stem Cell & Regenerative Medicine Congress, London2012 World Stem Cell & Regenerative Medicine Congress, London
2012 World Stem Cell & Regenerative Medicine Congress, London
 
Roth Capital 24th Annual Growth Stock Conference, Los Angeles
Roth Capital 24th Annual Growth Stock Conference, Los AngelesRoth Capital 24th Annual Growth Stock Conference, Los Angeles
Roth Capital 24th Annual Growth Stock Conference, Los Angeles
 
Regenerative Medicine Track at Biotech Showcase 2012, San Francisco
Regenerative Medicine Track at Biotech Showcase 2012, San FranciscoRegenerative Medicine Track at Biotech Showcase 2012, San Francisco
Regenerative Medicine Track at Biotech Showcase 2012, San Francisco
 
Presentation at Stem Cell Meeting on the Mesa, La Jolla, Calif., November 30,...
Presentation at Stem Cell Meeting on the Mesa, La Jolla, Calif., November 30,...Presentation at Stem Cell Meeting on the Mesa, La Jolla, Calif., November 30,...
Presentation at Stem Cell Meeting on the Mesa, La Jolla, Calif., November 30,...
 
Presentation at Stem Cells USA & Regenerative medicine Congress 2011 in Bosto...
Presentation at Stem Cells USA & Regenerative medicine Congress 2011 in Bosto...Presentation at Stem Cells USA & Regenerative medicine Congress 2011 in Bosto...
Presentation at Stem Cells USA & Regenerative medicine Congress 2011 in Bosto...
 
Presentation at the Rodman & Renshaw Global Investment Conference, NYC, Sept....
Presentation at the Rodman & Renshaw Global Investment Conference, NYC, Sept....Presentation at the Rodman & Renshaw Global Investment Conference, NYC, Sept....
Presentation at the Rodman & Renshaw Global Investment Conference, NYC, Sept....
 
Presentation at World Stem Cell & Regenerative Medicine Congress, London. May...
Presentation at World Stem Cell & Regenerative Medicine Congress, London. May...Presentation at World Stem Cell & Regenerative Medicine Congress, London. May...
Presentation at World Stem Cell & Regenerative Medicine Congress, London. May...
 
Presentation at Bio-Europe Spring 2011 Conference, Milan, Italy. March 2011
Presentation at Bio-Europe Spring 2011 Conference, Milan, Italy. March 2011Presentation at Bio-Europe Spring 2011 Conference, Milan, Italy. March 2011
Presentation at Bio-Europe Spring 2011 Conference, Milan, Italy. March 2011
 
Presentation at BIO CEO & Investor Conference, New York City. February 2011
Presentation at BIO CEO & Investor Conference, New York City. February 2011Presentation at BIO CEO & Investor Conference, New York City. February 2011
Presentation at BIO CEO & Investor Conference, New York City. February 2011
 

Recently uploaded

ethnographic research. A step by step guide for students who want to know abo...
ethnographic research. A step by step guide for students who want to know abo...ethnographic research. A step by step guide for students who want to know abo...
ethnographic research. A step by step guide for students who want to know abo...legal
 
Monthly Social Media Update March 2024 - Luan.pptx
Monthly Social Media Update March 2024 - Luan.pptxMonthly Social Media Update March 2024 - Luan.pptx
Monthly Social Media Update March 2024 - Luan.pptxAndy Lambert
 
Cafagno_Nicholas_SC_PB1_2024-03 (1).pptx
Cafagno_Nicholas_SC_PB1_2024-03 (1).pptxCafagno_Nicholas_SC_PB1_2024-03 (1).pptx
Cafagno_Nicholas_SC_PB1_2024-03 (1).pptxnlcafagno
 
Lecture_6.pptx English speaking easyb to
Lecture_6.pptx English speaking easyb toLecture_6.pptx English speaking easyb to
Lecture_6.pptx English speaking easyb toumarfarooquejamali32
 
Live-Streaming in the Music Industry Webinar
Live-Streaming in the Music Industry WebinarLive-Streaming in the Music Industry Webinar
Live-Streaming in the Music Industry WebinarNathanielSchmuck
 
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISINGUNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISINGlokeshwarmaha
 
Chapter_Five_The_Rural_Development_Policies_and_Strategy_of_Ethiopia.pptx
Chapter_Five_The_Rural_Development_Policies_and_Strategy_of_Ethiopia.pptxChapter_Five_The_Rural_Development_Policies_and_Strategy_of_Ethiopia.pptx
Chapter_Five_The_Rural_Development_Policies_and_Strategy_of_Ethiopia.pptxesiyasmengesha
 
Personal Brand Exploration Presentation.
Personal Brand Exploration Presentation.Personal Brand Exploration Presentation.
Personal Brand Exploration Presentation.cleomatise
 
Mastering Enterprise CMS Development: A Comprehensive Guide
Mastering Enterprise CMS Development: A Comprehensive GuideMastering Enterprise CMS Development: A Comprehensive Guide
Mastering Enterprise CMS Development: A Comprehensive GuideSynapseIndia
 
The Importance of entrepreneurial storytelling
The Importance of entrepreneurial storytellingThe Importance of entrepreneurial storytelling
The Importance of entrepreneurial storytellingP&CO
 
Trend Marketing 2024_Inisago_RosalinaOmega
Trend Marketing 2024_Inisago_RosalinaOmegaTrend Marketing 2024_Inisago_RosalinaOmega
Trend Marketing 2024_Inisago_RosalinaOmegaRosalinaOmega
 
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfAMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfJohnCarloValencia4
 
How Solar Energy Benefits Hospitals.
How  Solar  Energy  Benefits  Hospitals.How  Solar  Energy  Benefits  Hospitals.
How Solar Energy Benefits Hospitals.Contendre Solar
 
(HBR Guide to) Harvard Business Review - HBR Guide to Critical Thinking-Harva...
(HBR Guide to) Harvard Business Review - HBR Guide to Critical Thinking-Harva...(HBR Guide to) Harvard Business Review - HBR Guide to Critical Thinking-Harva...
(HBR Guide to) Harvard Business Review - HBR Guide to Critical Thinking-Harva...Rifki Hanif
 
Personal Brand Exploration - Regina Aparicio
Personal Brand Exploration - Regina AparicioPersonal Brand Exploration - Regina Aparicio
Personal Brand Exploration - Regina Aparicioaparicioregina7
 
Building Your Personal Brand on LinkedIn - Expert Planet- 2024
 Building Your Personal Brand on LinkedIn - Expert Planet-  2024 Building Your Personal Brand on LinkedIn - Expert Planet-  2024
Building Your Personal Brand on LinkedIn - Expert Planet- 2024Stephan Koning
 
Team B Mind Map for Organizational Chg..
Team B Mind Map for Organizational Chg..Team B Mind Map for Organizational Chg..
Team B Mind Map for Organizational Chg..dlewis191
 
Laboy Rolon RIcardo MBBS 2024-06 Presentation
Laboy Rolon RIcardo MBBS 2024-06 PresentationLaboy Rolon RIcardo MBBS 2024-06 Presentation
Laboy Rolon RIcardo MBBS 2024-06 Presentationrickylaboy2005
 
Puppet Maker Puppet Maker
Puppet Maker                Puppet MakerPuppet Maker                Puppet Maker
Puppet Maker Puppet Makerqasimishaq8
 
The Canvas of Creative Mastery Newsletter_March 2024
The Canvas of Creative Mastery Newsletter_March 2024The Canvas of Creative Mastery Newsletter_March 2024
The Canvas of Creative Mastery Newsletter_March 2024AmirYakdi
 

Recently uploaded (20)

ethnographic research. A step by step guide for students who want to know abo...
ethnographic research. A step by step guide for students who want to know abo...ethnographic research. A step by step guide for students who want to know abo...
ethnographic research. A step by step guide for students who want to know abo...
 
Monthly Social Media Update March 2024 - Luan.pptx
Monthly Social Media Update March 2024 - Luan.pptxMonthly Social Media Update March 2024 - Luan.pptx
Monthly Social Media Update March 2024 - Luan.pptx
 
Cafagno_Nicholas_SC_PB1_2024-03 (1).pptx
Cafagno_Nicholas_SC_PB1_2024-03 (1).pptxCafagno_Nicholas_SC_PB1_2024-03 (1).pptx
Cafagno_Nicholas_SC_PB1_2024-03 (1).pptx
 
Lecture_6.pptx English speaking easyb to
Lecture_6.pptx English speaking easyb toLecture_6.pptx English speaking easyb to
Lecture_6.pptx English speaking easyb to
 
Live-Streaming in the Music Industry Webinar
Live-Streaming in the Music Industry WebinarLive-Streaming in the Music Industry Webinar
Live-Streaming in the Music Industry Webinar
 
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISINGUNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
 
Chapter_Five_The_Rural_Development_Policies_and_Strategy_of_Ethiopia.pptx
Chapter_Five_The_Rural_Development_Policies_and_Strategy_of_Ethiopia.pptxChapter_Five_The_Rural_Development_Policies_and_Strategy_of_Ethiopia.pptx
Chapter_Five_The_Rural_Development_Policies_and_Strategy_of_Ethiopia.pptx
 
Personal Brand Exploration Presentation.
Personal Brand Exploration Presentation.Personal Brand Exploration Presentation.
Personal Brand Exploration Presentation.
 
Mastering Enterprise CMS Development: A Comprehensive Guide
Mastering Enterprise CMS Development: A Comprehensive GuideMastering Enterprise CMS Development: A Comprehensive Guide
Mastering Enterprise CMS Development: A Comprehensive Guide
 
The Importance of entrepreneurial storytelling
The Importance of entrepreneurial storytellingThe Importance of entrepreneurial storytelling
The Importance of entrepreneurial storytelling
 
Trend Marketing 2024_Inisago_RosalinaOmega
Trend Marketing 2024_Inisago_RosalinaOmegaTrend Marketing 2024_Inisago_RosalinaOmega
Trend Marketing 2024_Inisago_RosalinaOmega
 
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfAMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
 
How Solar Energy Benefits Hospitals.
How  Solar  Energy  Benefits  Hospitals.How  Solar  Energy  Benefits  Hospitals.
How Solar Energy Benefits Hospitals.
 
(HBR Guide to) Harvard Business Review - HBR Guide to Critical Thinking-Harva...
(HBR Guide to) Harvard Business Review - HBR Guide to Critical Thinking-Harva...(HBR Guide to) Harvard Business Review - HBR Guide to Critical Thinking-Harva...
(HBR Guide to) Harvard Business Review - HBR Guide to Critical Thinking-Harva...
 
Personal Brand Exploration - Regina Aparicio
Personal Brand Exploration - Regina AparicioPersonal Brand Exploration - Regina Aparicio
Personal Brand Exploration - Regina Aparicio
 
Building Your Personal Brand on LinkedIn - Expert Planet- 2024
 Building Your Personal Brand on LinkedIn - Expert Planet-  2024 Building Your Personal Brand on LinkedIn - Expert Planet-  2024
Building Your Personal Brand on LinkedIn - Expert Planet- 2024
 
Team B Mind Map for Organizational Chg..
Team B Mind Map for Organizational Chg..Team B Mind Map for Organizational Chg..
Team B Mind Map for Organizational Chg..
 
Laboy Rolon RIcardo MBBS 2024-06 Presentation
Laboy Rolon RIcardo MBBS 2024-06 PresentationLaboy Rolon RIcardo MBBS 2024-06 Presentation
Laboy Rolon RIcardo MBBS 2024-06 Presentation
 
Puppet Maker Puppet Maker
Puppet Maker                Puppet MakerPuppet Maker                Puppet Maker
Puppet Maker Puppet Maker
 
The Canvas of Creative Mastery Newsletter_March 2024
The Canvas of Creative Mastery Newsletter_March 2024The Canvas of Creative Mastery Newsletter_March 2024
The Canvas of Creative Mastery Newsletter_March 2024
 

ACTC Company Presentation, July 2007

  • 2. 2 This presentation contains “forward-looking statements” as defined under the federal securities laws. Actual results could vary materially. Factors that could cause actual results to vary materially are described in our filings with the Securities and Exchange Commission. You should pay particular attention to the “risk factors” contained in documents we file from time to time with the Securities and Exchange Commission. The risks identified therein, as well as others not identified by the Company, could cause the Company’s actual results to differ materially from those expressed in any forward-looking statements. Legal NoticeLegal Notice Cautionary Statement Concerning Forward-Looking Statements
  • 3. 3 Stem Cell Based TherapyStem Cell Based Therapy Scientists worldwide believe stem cell- based therapies have the potential to restore healthy function of diseased or damaged tissues Goal is to develop therapies that work by transplanting cells and tissues derived from stem cells into the body, using the body’s natural powers of regeneration and healing
  • 4. 4 Company MissionCompany Mission Translating World Class Stem Cell Research into Proprietary Human Therapeutic Programs
  • 5. 5 Recent EventsRecent Events Driving Forward into the Clinic Acquiring Mytogen and Myoblast Program Phase II Clinical Trial for the Treatment of Chronic Heart Failure Commencing GLP Studies for RPE Program Preclinical Safety Studies for the Treatment of AMD and Retinal Degenerative Disease Commencing Preclinical Studies for Hemangioblast Program Preclinical Studies for the Replacement of Red Blood Cells and the Treatment of Eye Disease (Diabetic Retinopathy and Branch Vein Occlusion)
  • 6. 6 Key Highlights of Mytogen AcquisitionKey Highlights of Mytogen Acquisition Target Market for Myoblast Program Chronic Heart Failure - treat scar tissue caused by heart attack Clearance from FDA to Proceed with Phase II Clinical Trials Experienced Mytogen Development Team – Together for over Ten Years Strong Intellectual Property – Mytogen Licensed from GenVec who Acquired from Diacrin Transaction to Close in July – ACT Acquiring Mytogen for Common Stock Charlestown, MA GMP Facility
  • 7. 7 Key Highlights of Mytogen AcquisitionKey Highlights of Mytogen Acquisition Gained Clearance from FDA to Proceed with Phase II Multi-Center Clinical Trial 3 Phase I Clinical Studies Completed Dosed in 42 patients No safety concerns Strong indications of efficacy Phase lb Catheter Trial Nearly Complete No adverse effects associated with cells, no arrhythmia concerns Highly significant improvement in NYHA classification Improvement in ventricular volumes 2.8 2.4 1.9 2.4 1.4 2.6 1 1.5 2 2.5 3 Myoblast Control AverageNYHAClass 3 mos: p = 0.0009, n = 23 6 mos: p < 0.0001, n = 23 A decrease in NYHA score represents an improvement in symptoms and an increase represents a worsening. Phase Ib Clinical Trial Results – NYHA Classification
  • 8. 8 Key Investment HighlightsKey Investment Highlights ACT Proprietary Human Therapeutic Programs Myoblast Program Treatment of Heart Attack Phase II and Heart Failure RPE Program Treatment of AMD and Retinal Preclinical Degenerative Diseases Hemangioblast Treatment of Disease and Disorders Preclinical Program of the Blood and Vascular System Dermal Program Treatment of Wounds, Burns Preclinical and Scars
  • 9. 9 Key Investment HighlightsKey Investment Highlights ACT Proprietary Enabling Technology Platforms Blastomere Program First Proven Alternative Method for hESC Derivation ACTCellerate High Throughput Derivation and Differentiation of Program Therapeutic Cell Types GMP Manufacturing Producing GMP-Compliant, Pathogen-Free Banks Program of hESCs and Therapeutic Cell Types
  • 10. 10 World Class Scientific Team Lead By: Dr. Michael West President and Chief Scientific Officer Dr. Robert Lanza VP of Research & Scientific Development Dr. Pedro Huertas Chief Development Officer Industry-Leading Intellectual Property Portfolio More than 300 patents and patent applications related to stem cell therapy and regenerative medicine Key Investment HighlightsKey Investment Highlights
  • 12. 12 Myoblast Stem Cell TherapyMyoblast Stem Cell Therapy Outpatient therapy to improve cardiac function in heart failure patients Harvest muscle stem cells (Myoblasts) from patient’s thigh Expand cells using proprietary culturing process Identify and map scarred regions of the heart with 3-D imaging technique Inject cells with minimally-invasive cardiac catheter: no general anesthesia
  • 13. 13 Myoblast Clinical Trial SummaryMyoblast Clinical Trial Summary Escalating - 30, 100, 300 and 600 MM Cells Single Dose - 300 MM Cells Escalating – 10, 30, 100 and 300 MM Cells Single Dose - 300 MM Cells Dose Safe at all doses, improved symptoms and function Safety Catheter Injection 23 Patients (12 treated, 11 control) Phase 1b Catheter Result Primary Endpoint Indication Patients Phase 1b CABG Phase 1 CABG Phase 1 LVAD Survival of cells (cardiac imaging), improved symptoms and function Dose escalation, Safe at all doses Demonstrated cell survival in humans SafetySafetySafety +CABG+CABG LVAD Bridge to Transplant 12 patients12 patients6 patients
  • 14. 14 Phase Ib Catheter Trial SummaryPhase Ib Catheter Trial Summary First U.S. randomized trial of catheter-delivered muscle cells Core laboratory analysis of objective endpoints Only trial with direct injection into scar (other stem cells must be delivered to viable tissue for benefit) Catheter delivery process without any complications No deaths, no loss to follow-up Ongoing follow-up data
  • 15. 15 3-D NOGA Mapping of Myoblast Injections3-D NOGA Mapping of Myoblast Injections 5.7 mV 8.6 mV Injections of 600 million cells into infarct region shown in red 3 months post reveals significant improvement in viability of the heart
  • 16. 16 Phase Ib Clinical Trial ResultsPhase Ib Clinical Trial Results 2.8 2.4 1.9 2.4 1.4 2.6 1 1.5 2 2.5 3 Myoblast Control AverageNYHAClass 3 mos: p = 0.0009, n = 23 6 mos: p < 0.0001, n = 23 A decrease in NYHA score represents an improvement in symptoms and an increase represents a worsening NYHA Classification of Heart Failure Symptoms Baseline 3mos 6mos Baseline 3mos 6mos
  • 17. 17 Phase Ib Clinical Trial ResultsPhase Ib Clinical Trial Results -0.6 -0.4 -1 -1.4 0.2 -1.6 -1.4 -1.2 -1 -0.8 -0.6 -0.4 -0.2 0 0.2 0.4 Ave.ChangeinNYHA Control ß-blockers ACE Inhibitors CRT Myoblasts Control ß-blockers* ACE Inhibitors# CRT† Myoblasts * Lombardo et al., 2006 Am J Cardiovasc Drugs 6:259-63 † McAllister et al., 2004 Ann Intern Med 141:381-90 # Sliwa et al., 2004 JACC 44:1825-30 Change in NYHA at 6mos post treatment Comparative Effects of Heart Failure Treatments on NYHA
  • 18. 18 Phase Ib Clinical Trial ResultsPhase Ib Clinical Trial Results Minnesota Living with Heart Failure Questionnaire (MLHFQ) 47 47 28 46 0 10 20 30 40 50 Myoblast Control p = 0.017, n = 23 Baseline 6mos Baseline 6mos * Improvement in patient quality of life (QOL) scores for all patients
  • 19. 19 Phase Ib Clinical Trial ResultsPhase Ib Clinical Trial Results Average change in distance walked in 6 minutes from 3 months to 6 months for all patients 81 -9 -50 0 50 100 Feet Myoblast Control 6 Minute Walk Test
  • 20. 20 Phase Ib Clinical Trial ResultsPhase Ib Clinical Trial Results Ventrical Volumes: End Systolic and End Diastolic Diameters End Systolic Diameter at 3 and 6 mos as measured by independent echocardiography core lab for all patients 5.52 4.89 5.4 4.99 5.41 5.08 4.8 4.9 5 5.1 5.2 5.3 5.4 5.5 5.6 Myoblast Control cm p = 0.06, n = 23 Baseline 3mos 6mos Baseline 3mos 6mos End Diastolic Diameter at 3 and 6 mos as measured by independent echocardiography core lab for all patients 6.41 6.2 6.38 6.27 6.39 6.37 6 6.1 6.2 6.3 6.4 6.5 Myoblast Control cm p = 0.07, n = 23 Baseline 3mos 6mos Baseline 3mos 6mos
  • 21. 21 Phase Ib Clinical Trial ResultsPhase Ib Clinical Trial Results NYHA Classification at 6 month vs Baseline for all Patients 36%64%0%Control 0%17%83%Myoblast WorsenedNo ChangeImproved
  • 22. 22 Plan for Phase II Clinical TrialPlan for Phase II Clinical Trial 160 total patients (2:1 treatment vs control) Double-blind, placebo (sham procedure) controlled Catheter delivery of cells: percutaneous Three month, six month, and 12 month follow-up Endpoints: Improvement in HF symptoms and Ventricular Volumes Primary endpoint: Improvement in quality of life measure “Kansas City Cardiomypathy Questionaire” Secondary endpoints: Ventricular volumes, Six minute walk test Interim data analysis at six months by Independent Review Board
  • 24. 24 RPE Anatomy and FunctionRPE Anatomy and Function RPE Layer Deteriorates in Patients with AMD and other Retinal Degenerative Diseases absorption of stray light barrier vitamin A metabolism and transport phagocytosis of shed photoreceptor segments some functions of RPE
  • 25. 25 RPE ProgramRPE Program 2006 Milestone Achieved: Published Data Showing hESC- derived RPE Cells Rescue Visual Function in RCS Rats
  • 26. 26 RPE Rescue in the RCS RatRPE Rescue in the RCS Rat RPE: essential for the survival of photoreceptors in the retina; believed to play a critical role in healthy vision RCS retina at P100 with RPE-9 injection: A: low power view of retina showing extensive rescue; B: high power of outline b showing rescued photoreceptors; C: high power of outline c showing non-rescue area. Photoreceptor Rescue in RCS Rat by transplanted H9-RPE cells
  • 27. 27 RPE Program CollaborationRPE Program Collaboration 2007 Milestone Achieved - Preclinical Development Collaboration with Casey Eye Institute at Oregon Health & Science University Dr. Raymond Lund Leading Researcher in Retinal Degenerative Disease Dr. Peter Francis Senior Researcher and Clinician Dr. Richard Weleber Senior Clinician OHSU Team is Conducting Dosage Studies in the RCS Rat OHSU Team is Advising on RPE Program Safety Studies Additionally, OHSU Team is Advising on Plans for IND and Phase I Human Clinical Trials
  • 28. 28 RPE Program - GLP Safety StudiesRPE Program - GLP Safety Studies 2007 Milestone Achieved – Hired MPI Research to conduct our GLP Safety Studies for the RPE Program Initial Pilot Studies Commenced initial studies to demonstrate cell survival and validation of controls Pivotal Studies Full safety and tumorigenicity studies to demonstrate safety of cells in animal models FDA Dialogue Company has initiated discussions with FDA and is planning for further discussions in 2007 in regard to IND submission
  • 30. 30 The Hemangioblast CellThe Hemangioblast Cell Pre-cursor to all cell types of the blood and the vascular system
  • 31. 31 Hemangioblast ProgramHemangioblast Program 2006 Milestone Achieved: Hemangioblast Cells Generated from Blastomere Derived hESC Lines 40X 10X
  • 32. 32 Hemangioblast ProgramHemangioblast Program 2007 Milestone Achieved: Published Data Showing Hemangioblast Function In Vivo in Nature Methods
  • 33. 33 Hemangioblast ProgramHemangioblast Program Repair of Ischemic Retinal Vasculatures Mouse Rat
  • 34. 34 Hemangioblast ProgramHemangioblast Program Restoration of Blood Flow in Ischemic Limbs (Rat)
  • 35. 35 Hemangioblast ProgramHemangioblast Program Increase in Survival Rate in Infacted Heart (Mouse)
  • 36. 36 Hemangioblast ProgramHemangioblast Program Significant Breakthrough in Scaled Manufacture of Hemangioblasts Cells Well characterized - make all cells of the blood and vascular tissues Significant Collaborations underway to generate proof of concept data in a wide range of indications Plan to generate Hemangioblasts under GMP in 2007 and commence additional preclinical studies for target indications
  • 38. 38 Skin: Dermal Cells for Wound and Burn RepairSkin: Dermal Cells for Wound and Burn Repair ES dermal cells possess unique healing capacities of early skin cells to heal wounds without scarring. ACTC is researching ES dermal cell technology that may someday repair skin. Large application for therapies to repair damage from burns, wounds and surgical procedures, quickly and without scarring Cells successfully isolated in our California labs
  • 41. 41 Success in HumanSuccess in Human 2006 Milestone Achieved: Derivation of Human hESC Lines Published in Nature
  • 42. 42 First Proven Alternative MethodFirst Proven Alternative Method Enables Derivation of New hESC Lines via Preimplantation Genetic Diagnosis (PGD) Method, Preserving Development Potential of the Embryo First Proven Alternative; Presents Solution to hESC Controversy Blastomere hESC Lines May Be Eligible for Federal Funding; Company Seeking RulingHemangioblastsHemangioblasts Differentiated fromDifferentiated from BlastomereBlastomere hESChESC LinesLines
  • 44. 44 ACTCellerate – A Sleeping BeautyACTCellerate – A Sleeping Beauty 2006 Milestone Achieved: Announced proprietary high throughput technology platform for discovering large number of therapeutically useful, hESC-derived cell types
  • 45. 45 ACTCellerate ProgramACTCellerate Program Cell Sorting Cell Sorting Gene Expression Profile Scaling in Rollers hES Cell Line ACTCellerate Cell Lines LinesHuman Embryo- Derived Cells
  • 46. 46 ACTCellerate ProgramACTCellerate Program ACT162 Cardiac Progenitor Cardiac Muscle ACTC MYH7 MYL4 MYH3 TNNT2 Neuronal NEF3 NEFL MEIS1 CDH2 SILV ACTCellerate Cell Lines Lines
  • 48. 48 CENTRIF CT03002 Microscope BSC SH- 01002 BSC SH- 01001 Viewing Window Sterilizer OV-05001 CENTRIF CT-03001 Unclassified Pass Thru Warming Oven IN-02001 -80 Freezer CS-04002 2-8˚C Refrigerator CS-01001 Tri-Gas Incubator IN-03001 CO2 INCUBATOR IN-01004 (top) IN-01003 (bottom) CO2 INCUBATOR IN-01001 (top) IN-01002 (bottom) Microscope with Computer Work Station SH- 03001 BSC SH-01003 FPRM198Revision5 13June06 Class 10.000 Room 198 Class 100.000 Room 199 GMP Manufacturing ProgramGMP Manufacturing Program 2006 Milestone Achieved - Company Opens GMP Facilities in Massachusetts and California ADVANCED CELL TECHNOLOGY GMP MANUFACTURING LABORATORY Rms 198/199
  • 49. 49 GMP Manufacturing ProgramGMP Manufacturing Program 2007 Milestone Achieved – Company Hires Dr. Pedro Huertas as Chief Development Officer Noted Biotech Industry Executive – Experience at Genzyme, StemCells Inc., Novazyme, Amicus Therapeutics Harvard – MIT Trained Physician M.D. from Harvard and MIT Ph.D. from Harvard University in Cell and Developmental Biology M.B.A. from MIT’s Sloan School of Mgmt Tasked with leading company’s push to the clinic
  • 50. 50 GMP Manufacturing ProgramGMP Manufacturing Program Design of Master and Working hESC Banks Unlimited Expansion of Stem Cell Line Master Cell Bank Working Cell Bank Bank of Differentiated Cells Bank of Differentiated Cells Bank of Differentiated Cells Single Blastomere
  • 51. 51 GMP Manufacturing ProgramGMP Manufacturing Program 2007 Milestone Achieved – Company Manufacturing RPE Cells under GMP Compliant Conditions Working Stem Cell Bank Cryopreserved RPE Cell Bank Retinal Pigmented Epithelium
  • 53. 53 2007 – 2008 Corporate Milestones2007 – 2008 Corporate Milestones Raise Additional Capital Achieve Listing on National Exchange Commence Phase II Clinical Trial for Myoblast Program File INDs for RPE and Hemangioblast Programs Announce Significant Corporate Partnership Announce Scientific Breakthrough on Solving Histocompatibility
  • 54. 54 ACTC Value PropositionACTC Value Proposition Selected Comparable Companies (S mio., except per share data) Osiris OSIR / $14.04 27.4 $384.7 172,590 Phase II/III Stem Cell Therapy NASDAQ Geron Corporation GERN / $7.14 72.9 $520.5 1,660,000 Phase II Cancer / Preclinical hESCs NASDAQ Stem Cells, Inc. STEM / $2.30 80.4 $184.9 1,215,743 Phase I Stem Cell Therapy NASDAQ Aastrom Biosciences, Inc. ASTM / $1.35 120.0 $162.0 1,100,000 Phase II/III Stem Cell Therapy NASDAQ ViaCell, Inc. VIAC / $5.40 38.8 $209.5 151,298 Cord Blood Storage / Preclinical NASDAQ Advanced Cell Technology ACTC / $0.47 49.5 $23.3 1,006,000 Phase II Stem Cell Therapy / Preclinical hESCs OTCBB * Does not include outstanding options, warrants and other common stock equivalents. Volume Average DailyMarket Capitalization Primary Shares Outstanding*Name / Description / Phase Tkr / Exch Current Stock Price (Jun 28th)
  • 55. Thank you for your time For more information, visit www.advancedcell.com Advanced Cell Technology is traded on the OTC BB, symbol: ACTC